Browsing Department of Biomedicine by Author "McCormack, Emmet"
Now showing items 1-3 of 3
-
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis
Gausdal, Gro; Wergeland, Anita; Skavland, Jørn; Nguyen, Eric; Pendino, Frédéric; Rouhee, Nazanin; McCormack, Emmet; Herfindal, Lars; Kleppe, Rune; Havemann, Ursula; Schwede, Frank; Bruserud, Øystein; Gjertsen, Bjørn Tore; Lanotte, Michel; Ségal-Bendirdjian, Evelyne; Døskeland, Stein Ove (Peer reviewed; Journal article, 2013)We show that cyclic AMP (cAMP) elevating agents protect blasts from patients with acute promyelocytic leukemia (APL) against death induced by first-line anti-leukemic anthracyclines like daunorubicin (DNR). The cAMP effect ... -
Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model
Hofmann, Matthias; McCormack, Emmet; Mujic, Maja; Roßberg, Maila; Bernd, August; Bereiter-Hahn, Jürgen; Gjertsen, Bjørn Tore; Wiig, Helge; Kippenberger, Stefan (Peer reviewed; Journal article, 2009-08)Elevated tumor interstitial fluid pressure (TIFP) is a characteristic of most solid tumors. Clinically, TIFP may hamper the uptake of chemotherapeutic drugs into the tumor tissue reducing their therapeutic efficacy. In ... -
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
Poli, Aurélie; Wang, Jian; Domingues, Olivia; Planagumà, Jesús; Yan, Tao; Rygh, Cecilie Brekke; Skaftnesmo, Kai Ove; Thorsen, Frits Alan; McCormack, Emmet; Hentges, François; Pedersen, Paal-Henning; Zimmer, Jacques; Enger, Per Øyvind; Chekenya, Martha (Peer reviewed; Journal article, 2013-09-09)Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need ...